A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies
Cancer, 05/11/2012
Clinical Article
Pishvaian MJ et al. – Efatutazone demonstrates acceptable tolerability with evidence of disease control in patients with advanced malignancies.



